A patientâ€™s primary care physician and biochemical geneticist should follow growth and development regularly. Developmental delays should be identified and treated as early as possible.

Plasma amino acid levels should be regularly followed to guide dietary management by the biochemical geneticist in conjunction with a qualified metabolic nutritionist.

Complications of DLD deficiency including hepatomegaly, cardiomyopathy, and CNS changes require regular surveillance if present.

Patients receiving dichloroacetate (DCA) need to be monitored for the development of peripheral neuropathy [Shaag et al 1999, Stacpoole et al 2008].
